About tixagevimab + cilgavimab
Long-acting monoclonal antibodies
Used for
- Previously authorized in the United States to prevent COVID-19 before exposure in certain people.
- Not authorized in the United States for COVID-19 prevention or treatment as of 2023.
Usual adult dose
Previously, 300 mg of each antibody injected into separate muscles; repeat dosing depended on guidance.
Usual dose in children
Previously used for people aged 12 years or older weighing at least 40 kg; dose was 300 mg of each antibody.
Common side effects
- Injection-site pain, redness, or swelling
- Headache or fatigue
- Hypersensitivity reactions, including rare severe allergic reactions
- Rare serious heart-related events reported
Important warnings
- Authorization and availability vary by country and can change with circulating variants.
- Not a substitute for COVID-19 vaccination when vaccination is appropriate.
- Seek urgent care for severe allergic symptoms after an injection.
- Previously authorized doses may not work against resistant variants.
Pregnancy
Human pregnancy data are limited; use depended on whether potential benefit outweighed potential risk.
Breastfeeding
It is unknown whether these antibodies pass into breast milk; clinical data are limited.
Interactions
- No major drug interactions were identified; formal interaction studies were limited.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.